✦ LIBER ✦

597 Pharmacokinetics of the Novel FGFR and VEGFR Inhibitor, E-3810, in Patients with Advanced Solid Tumors Participating to a Phase I/II Trial

✍ Scribed by Zangarini, M.; Sala, F.; Camboni, M.G.; Cereda, R.; Livi, V.; Bahleda, R.; Dienstmann, R.; Delmonte, A.; D'Incalci, M.; Zucchetti, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of the safety and pharma

✍ Herbert I. Hurwitz; Roger B. Cohen; J. Patrick McGovren; Samit Hirawat; William 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 308 KB

Phase I, dose escalation and pharmacokin

✍ Noboru Yamamoto; Tomohide Tamura; Nobuyuki Yamamoto; Kazuhiko Yamada; Yasuhide Y 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 436 KB

381 A phase I study of BAY 43-90006, a n

✍ A. Awada; A. Hendlisz; T. Gil; B. Schwartz; S. Bartholomeus; E. Brendel; D. de V 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 147 KB

A phase I and pharmacokinetic study of t

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 141 KB

A Phase I study to assess the safety, to

✍ J. R. Infante; R. Kurzrock; J. Spratlin; H. A. Burris; S. G. Eckhardt; J. Li; K. 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 338 KB

218 POSTER A phase I dose-escalation stu

✍ E. Calvo; G. Edelman; J. Baselga; E. Kwak; C. Scheffold; L. Nguyen; G.I. Shapiro 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB